Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nektar up on Exubera data

NKTR was up $1.96 (17%) to $13.44 on 3.6 million shares on Monday after Pfizer (PFE) and Aventis (AVE) reported

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE